Importantly, cancer risk is not uniform: carriers of MLH1 and MSH2 variants generally face higher lifetime risk and penetrance than those with MSH6 or PMS2 variants, enabling gene-specific counseling and surveillance recommendations. The gene discussed is MLH1; the disease is cancer.